{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:10:57Z","timestamp":1791461457837,"version":"4.3.4"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>There is limited literature comparing the clinical parameters and treatment outcomes in HIV-infected and HIV-uninfected myasthenia gravis (MG) patients. The aim of the study was to investigate the clinical differences and treatment outcomes in the two categories of patients, particularly the safe use of immunosuppressive therapy in immunocompromised patients. The study was a retrospective analysis of medical records of MG patients from the neuromuscular unit at Inkosi Albert Luthuli Central Hospital in Kwa-Zulu Natal between 2003 and 2019. One hundred and seventy-eight (178) patients fulfilled the clinical criteria for MG. Twenty-four (13.4%) were HIV-infected and 154 (86.5%) were HIV-uninfected. There were 116 (65%) females, median 45 years, (IQR 40\u201362), 90 (50.5%) black African, 66 (37%) Indian, 20 (11.2%) white, and 2 (1.1%) of mixed ancestry. In the HIV-infected cohort, 20 (87%) had generalized MG, 12 (50%) bulbar, and 14 (60.9%) respiratory onset MG, 12 (50%) presented with MG Foundation of America (MGFA) class five diseases at diagnosis, six (25%) presented with MG crisis during the 5-year follow-up. Thirteen (54%) of the HIV-infected group required rescue therapy using (plasma exchange or IV immunoglobulin) combined with pulse cyclophosphamide compared with 17 (11%) in the HIV-uninfected cohort, respectively. At 5 years, 8 (33%) of the HIV-infected group remained refractory to treatment compared with 10 (6.5%) HIV-uninfected cohort, respectively. No adverse events were documented in HIV-infected patients receiving combination rescue therapy (PLEX or IVIG combined with IV cyclophosphamide). In conclusion HIV-infected MG patients are more likely to require combination rescue therapy with PE\/IVIG and IV cyclophosphamide compared with those who were HIV-uninfected. No side effects were documented in the HIV-infected group receiving the above therapy.<\/jats:p>","DOI":"10.3389\/fneur.2021.738813","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T05:08:47Z","timestamp":1634274527000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["A Comparison of Clinical, Electro-Diagnostic, Laboratory, and Treatment Outcome Differences in a Cohort of HIV-Infected and HIV-Uninfected Patients With Myasthenia Gravis"],"prefix":"10.3389","volume":"12","author":[{"given":"Kaminie","family":"Moodley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre L. A.","family":"Bill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in Myasthenia Gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/ene.13535","article-title":"A nationwide epidemiological study of myasthenia gravis in Latvia","volume":"25","author":"Zieda","year":"2018","journal-title":"Eur J Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.nmd.2007.07.002","article-title":"Myasthenia gravis in South Africans: racial differences in clinical manifestations","volume":"17","author":"Heckmann","year":"2007","journal-title":"Neuromuscul Disord."},{"key":"B4","unstructured":"2018"},{"key":"B5","first-page":"995","article-title":"HIV infection with myasthenia gravis","volume":"53","author":"Gorthi","year":"2005","journal-title":"J Assoc Physicians India."},{"key":"B6","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.clineuro.2011.03.019","article-title":"HIV-associated myasthenia gravis and impacts of HAART: one case report and a brief review","volume":"113","author":"Hung","year":"2011","journal-title":"Clin Neurol Neurosurg."},{"key":"B7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/CND.0b013e3181fb1be7","article-title":"Comorbid HIV and myasthenia gravis: case report and review of the literature","volume":"12","author":"Knopf","year":"2010","journal-title":"J Clin Neuromuscul Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.5692\/clinicalneurol.48.666","article-title":"Anti-MuSK antibody positive myasthenia gravis with HIV infection successfully treated with cyclosporin: a case report","volume":"48","author":"Kurokawa","year":"2008","journal-title":"Rinsho Shinkeigaku."},{"key":"B9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1017\/S0317167100034119","article-title":"Seronegative myasthenia gravis and human immunodeficiency virus infection: response to intravenous gamma globulin and prednisone","volume":"25","author":"Strong","year":"1998","journal-title":"Can J Neurol Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3389\/fneur.2020.00775","article-title":"Manangement issues in myastenia gravis patients living with HIV: a case series and literature review","volume":"11","author":"Heckmann","year":"2020","journal-title":"Front Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jns.2019.10.1080","article-title":"A rare case of musk myasthenia gravis in a HIV patient","volume":"405","author":"Aglave","year":"2019","journal-title":"J Neurol Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/mus.880180819","article-title":"Transient myasthenia gravis during HIV infection","volume":"18","author":"Authier","year":"1995","journal-title":"Muscle Nerve."},{"key":"B13","first-page":"A82","article-title":"A new immune reconstitution inflammatory syndrome (OROS): Myasthenia gravis (PAG) with antibodies against MuSK in an HIV-infected patient","volume":"70","author":"Carota","year":"2008","journal-title":"Neurology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.clinph.2007.11.173","article-title":"Co-occurrence of myasthenia gravis and HIV infection with normal CD4 counts","volume":"36","author":"Hayat","year":"2007","journal-title":"Muscle Nerve."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1093\/clinids\/20.6.1577","article-title":"Clin Infect Dis","volume":"20","year":"1995"},{"key":"B16","first-page":"395","article-title":"AIDS and myasthenia gravis: an exceptional association","volume":"147","author":"Martini","year":"1991","journal-title":"Rev Neurol."},{"key":"B17","first-page":"192","article-title":"Myasthenia gravis associated with HIV infection","volume-title":"Ryoikibetsu Shokogun Shirizu.","author":"Murai","year":"2001"},{"key":"B18","first-page":"456","article-title":"Occurrence of myasthenia in HIV infection 2 cases","volume":"144","author":"Tiab","year":"1993","journal-title":"Ann Med Interne."},{"key":"B19","first-page":"1355","article-title":"Myasthenia gravis associated with dual infection of HIV and HTLV-I","volume":"18","author":"Verma","year":"1995","journal-title":"Muscle Nerve."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1212\/NXI.0000000000000315","article-title":"comparative study of CIDP in a cohort of HIV-infected and HIV-uninfected patients","volume":"4","author":"Moodley","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jns.2018.12.030","article-title":"comparative study of motor neuron disease in HIV-infected and HIV-uninfected patients","volume":"397","author":"Moodley","year":"2019","journal-title":"J Neurol Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"992","DOI":"10.4102\/sajhivmed.v20i1.992","article-title":"Motor lumbosacral radiculopathy in HIV-infected patients","volume":"20","author":"Moodley","year":"2019","journal-title":"South Afr J HIV Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"903108","DOI":"10.12659\/AJCR.903108","article-title":"Comorbid human immunodeficiency virus (HIV) and muscle-specific kinase (MuSK) myasthenia gravis: a case report and literature review","volume":"18","author":"Sherpa","year":"2017","journal-title":"Am J Case Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e5769","DOI":"10.1097\/MD.0000000000005769","article-title":"Autoimmune diseases and HIV infection: a cross-sectional study","volume":"96","author":"Virot","year":"2017","journal-title":"Medicine."},{"key":"B25","doi-asserted-by":"publisher","first-page":"595068","DOI":"10.3389\/fimmu.2020.595068","article-title":"Case report: orbital myositis and myasthenia gravis as symptoms of immune reconstitution inflammatory syndrome in a patient with human immunodeficiency virus infection","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s13760-020-01461-9","article-title":"Dysphagia and respiratory failure in an HIV patient: MuSK myasthenia gravis","volume":"120","author":"Wirtz","year":"2020","journal-title":"Acta Neurol Belg."},{"key":"B27","article-title":"Enhanced Progress Report: National Strategic Plan on HIV and TB Pretoria: DoH","year":"2016"},{"key":"B28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.13544","article-title":"Rationale for the clinical guidelines for myasthenia gravis in Japan","volume":"1413","author":"Murai","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B29","first-page":"440","article-title":"A simple manual muscle test for myasthenia gravis - Validation and comparison with the QMG score. In: Agius MA, Richman DP, Fairclough RH, Maselli RA, editors","volume-title":"Myasthenia Gravis and Related Disorders: Biomchemical Basis for Disease of the Neuromuscular Junction.","author":"Sanders","year":"2003"},{"key":"B30","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/mus.21053","article-title":"Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve."},{"key":"B31","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"Still a relevant outcome measure","volume":"44","author":"Muppidi","year":"2011","journal-title":"Muscle Nerve."},{"key":"B32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/978-3-319-73585-6","article-title":"Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry","volume":"58","author":"Lee","year":"2018","journal-title":"Muscle Nerve."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1756286419832242","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord."},{"key":"B35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"key":"B36","doi-asserted-by":"publisher","first-page":"7557","DOI":"10.4314\/ajns.v23i2.7557","article-title":"Possible myasthenia and LEMS in the same patient","volume":"23","author":"Patel","year":"2005","journal-title":"Afr J Neurol Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/00002030-198808000-00015","article-title":"ten Veen JH, Brutel de la Riviere G. Complete remission of an AIDS-related B-cell lymphoma with one course of chemotherapy followed by zidovudine treatment","volume":"2","author":"van","year":"1988","journal-title":"AIDS."},{"key":"B38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/QAI.0b013e3182a03e9b","article-title":"Treatment outcomes in AIDS-related diffuse large B-cell lymphoma in the setting roll out of combination antiretroviral therapy in South Africa","volume":"64","author":"de","year":"2013","journal-title":"J Acquir Immune Defic Syndr."},{"key":"B39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1086\/595006","article-title":"HIV\/AIDS: immune reconstitution inflammatory syndrome: a reappraisal","volume":"48","author":"French","year":"2009","journal-title":"Clin Infect Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00415-015-7639-1","article-title":"MuSK myasthenia gravis as a manifestation of immune restoration disease in an HIV-positive patient","volume":"262","author":"Ragunathan","year":"2015","journal-title":"J Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/brain\/awq365","article-title":"Pathogenesis of the immune reconstitution inflammatory syndrome affecting the central nervous system in patients infected with HIV","volume":"134","author":"Martin-Blondel","year":"2011","journal-title":"Brain."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1089\/aid.2014.0106","article-title":"The immune pathogenesis of immune reconstitution inflammatory syndrome associated with highly active antiretroviral therapy in AIDS","volume":"30","author":"Zheng","year":"2014","journal-title":"Aids Res Hum Retrov."},{"key":"B43","first-page":"1329","article-title":"The thymus in acquired immune deficiency syndrome. Comparison with other types of immunodeficiency diseases, and presence of components of human immunodeficiency virus type 1","volume":"134","author":"Schuurman","year":"1989","journal-title":"Am J Pathol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/WCO.0b013e328364d6cd","article-title":"Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation","volume":"26","author":"Le","year":"2013","journal-title":"Curr Opin Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3389\/fneur.2020.00660","article-title":"MuSK-associated myasthenia gravis: clinical features and management","volume":"11","author":"Rodolico","year":"2020","journal-title":"Front Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/mus.26985","article-title":"Clinical features of LRP4\/agrin-antibody-positive myasthenia gravis: a multicenter study","volume":"62","author":"Rivner","year":"2020","journal-title":"Muscle Nerve."},{"key":"B47","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1212\/WNL.0b013e31820d6290","article-title":"Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis","volume":"76","author":"Kuntzer","year":"2011","journal-title":"Neurology."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.738813\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T05:09:00Z","timestamp":1634274540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.738813\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":47,"alternative-id":["10.3389\/fneur.2021.738813"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.738813","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]},"article-number":"738813"}}